| |

The Power of Immunotherapy: T Cells and Mesothelioma Treatment

ByHolly Zink
The Power of Immunotherapy: T Cells and Mesothelioma Treatment

Mesothelioma patients with more immune cells called CD8+ T cells might respond better to immunotherapy.

This is the finding of a team of scientists from Japan. Their study was published in the scientific journal Thoracic Cancer.

Typical Treatment Plan

Mesothelioma is a type of cancer that is both rare and aggressive. It grows in the cells lining the surface of organs like the lungs. Mesothelioma is caused by exposure to a toxic mineral called asbestos.

Because it is rare and grows quickly, mesothelioma can be hard for doctors to diagnose and treat. A patient usually needs to have many tests before a doctor can diagnose them with mesothelioma. This can include imaging scans, blood tests, and biopsies.

Once mesothelioma has been diagnosed, a typical treatment plan will include surgery, chemotherapy, and radiation therapy.

Unlocking the Power of Immunotherapy

Immunotherapy has emerged in the last decade as a new treatment option. It is also referred to as biological therapy. It uses the patient’s immune system to treat mesothelioma.

Immune checkpoint inhibitors are a form of immunotherapy. One of the reasons mesothelioma tumors can grow out of control is their ability to trick the immune system. Immune checkpoint inhibitors block mesothelioma’s built-in resistance to immune system attack. They are among the most promising approaches to combating this aggressive cancer.

In this new study, scientists wanted to find out why some patients respond well to immune checkpoint inhibitors while others do not. They looked at tissue samples from 22 patients who were treated with a specific immune checkpoint inhibitor called nivolumab. Out of these patients, four had a good response to the treatment, and 18 did not.

Next, the scientists examined different types of immune cells in the tumors. They found that patients who responded well to the treatment had more of a specific type of immune cell called CD8+ T cells.

This might mean that the types of immune cells and their location in the tumor may help doctors predict how well a patient will respond to immunotherapy.

Source

Yin Y, Sakakibara R, Honda T, et al. High density and proximity of CD8+ T cells to tumor cells are correlated with better response to nivolumab treatment in metastatic pleural mesothelioma [published online ahead of print, 2023 May 30]. Thorac Cancer. 2023;10.1111/1759-7714.14981. doi:10.1111/1759-7714.14981. https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.14981

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…